 |
|
|
|
 |
|
|
| Article 1 to 10 out of 20 concerning Abbott Laboratories
|
-
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
(06/17/2008)
Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA(R) (adalimumab) reduced the signs and symptoms of ankylosing ...
-
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
(03/11/2008)
Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer
Abbott announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) ...
-
OncoMethylome Sciences to Profile DNA for Abbott Oncology Compounds
(12/18/2007)
OncoMethylome Sciences entered into a pharmacogenomic service collaboration with Abbott. Under the terms of the collaboration, OncoMethylome will assist Abbott in profiling tumors. Specifically, OncoMethylome will be testing its DNA methylation ...
-
Orion's partner discontinues development of levosimendan (Simdax) in the US
(04/27/2007)
Orion has been informed by Abbott, the license holder for the intravenously administered formulation of levosimendan (trade name Simdax), an Orion-originated compound for acute decompensated heart failure, that Abbott has decided not to continue the ...
-
Innogenetics receives unanimous verdict against Abbott
(09/05/2006)
On Friday, September 1, 2006, a Jury unanimously upheld the validity of Innogenetics' patent, U.S. Patent No. 5,846,704 ("the '704 patent"), which claims a method of genotyping the Hepatitis C Virus ("HCV"). The dispute began in September 2005 when ...
-
Myriad and Abbott Enter Into Broad Discovery Collaboration
(04/13/2006)
Myriad Genetics, Inc. and Abbott announced that the two companies have entered into a broad drug discovery collaboration to identify novel therapeutic targets. The collaboration will leverage proprietary technology from both organizations to ...
-
Abbott Has Selected Two Additional Cancer Targets From Celera Genomics For Further Development
(02/20/2006)
Seven Celera Genomics Antigens Now in Research Pipeline with Partners
Celera Genomics Group, an Applera Corporation business, announced that Abbott has selected two Celera antigen targets for further investigation and potential therapeutic development. These are in addition to the two targets Abbott selected for ...
-
Celera Genomics Acquires Full Ownership of Celera Diagnostics Joint Venture
(01/11/2006)
Celera Genomics to Partner or Sell Small Molecule Drug Development Programs
Applera Corporation announced that its Board of Directors has approved a restructuring of its Celera Diagnostics joint venture, whereby, effective January 1, 2006, Celera Genomics acquired Applied Biosystems' 50 percent interest in the joint venture ...
-
Cipher reaches agreement to dismiss patent litigation in United States for CIP-Fenofibrate
(06/01/2005)
Cipher Pharmaceuticals Inc. announced that it has reached an agreement with Abbott Laboratories, Fournier Industrie et Santé and Laboratoires Fournier S.A. to dismiss all claims in the U.S. patent litigation related to CIP-Fenofibrate, Cipher's ...
-
Abbott Data Reveals a Promising New Approach in the Fight Against Cancer
(05/18/2005)
New preclinical data published in the current advanced online version of the journal Nature show that an experimental compound, ABT-737, that blocks the action of a class of proteins known as the Bcl-2 family, may prove to be a valuable tool in the ...
Additional information
Abbott Laboratories
Abbott Park, Ill., United States of America
Company
|
|
|
|
|
|
Top
